HPRG Protein, Human (HEK293, His)

HPRG protein is a multifunctional plasma glycoprotein with the ability to bind multiple ligands, including heme, heparin, thrombospondin, etc. HPRG regulates immune processes, angiogenesis, coagulation, and fibrinolysis through zinc-dependent binding to heparin and glycosaminoglycans. HPRG Protein, Human (HEK293, His) is the recombinant human-derived HPRG protein, expressed by HEK293 , with C-His, C-10*His labeled tag. The total length of HPRG Protein, Human (HEK293, His) is 507 a.a., with molecular weight of 75-80 kDa.

The HPRG Protein is a versatile plasma glycoprotein with a diverse range of ligand-binding capabilities, including heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. It exhibits zinc-dependent binding to heparin and heparin/glycosaminoglycans and interacts with heparan sulfate on the surfaces of liver, lung, kidney, and heart endothelial cells. Acting as an adapter protein, HPRG is implicated in the regulation of numerous processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation, and fibrinolysis. HPRG also mediates the clearance of necrotic cells by enhancing phagocytosis in a heparan sulfate-dependent pathway, with regulation by specific ligands like heparin and zinc ions. Moreover, it binds to IgG subclasses, influencing their clearance and inhibiting the formation of insoluble immune complexes. Additionally, HPRG tethers plasminogen to cell surfaces, alters T-cell morphology, and modulates angiogenesis by blocking CD6-mediated antiangiogenic effects. Acting as a regulator in the vascular endothelial growth factor (VEGF) signaling pathway, HPRG inhibits endothelial cell motility and plays a role in tumor angiogenesis and immune surveillance, normalizing tumor vessels and promoting antitumor immunity by influencing tumor-associated macrophages.

Measured by the ability of the immobilized protein to support the adhesion of MOLT-4 human acute lymphoblastic leukemia cells in the presence of 10 μg/mL Concanvalin A. The ED₅₀ for this effect is 0.3239-1.166 μg/mL.

Human

HEK293

C-His

P04196/NP_000403.1 (V19-K525)

3273  [NCBI]

VSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK

75-80 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in PBS, pH 7.4. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.